State of the Art: Personalized Antiplatelet Therapy by Genotype and Platelet Function Testing
Catheterization and Cardiovascular Interventions · 05.08.2026
DOI: 10.1002/ccd.70794 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Catheterization and Cardiovascular Interventions, online erschienen am 05.08.2026. Verfasst von Paul A Gurbel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore and Lifebridge Health System, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Platelet Function Tests, Precision Medicine, Receptors, Purinergic P2Y12. Die Arbeit nennt 82 Literaturangaben.
Abstract (Originalsprache)
The platelet P2Y 12 receptor plays a critical role in the genesis of arterial thrombotic events. The demonstration of clopidogrel resistance and the relation of high platelet reactivity to ADP to recurrent ischemic event occurrences in patients with coronary artery disease treated with stents significantly influenced the development of potent P2Y 12 receptor inhibitors. A “one size fits all” strategy of clopidogrel therapy is associated with a greater risk for recurrent thrombotic events compared to uniform use of potent P2Y 12 receptor inhibitors which causes more bleeding. The concept of a therapeutic window for P2Y 12 inhibitor therapy that strikes a balance between the attenuation of thrombotic risk and bleeding has been used to personalize antiplatelet therapy. Despite the absence of a strong recommendation in the current guidelines for platelet function testing or genetic testing, the treating interventionalist must rely on the available evidence base, as summarized in this Review, to help decide whether to employ a one‐size‐fits‐all strategy of antiplatelet therapy or one that is personalized by objective testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore and Lifebridge Health System, Baltimore, Maryland, USA.
- Gwangmyeong and Department of Internal Medicine, CAU Thrombosis and Biomarker Center, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Seoul, South Korea.
- Department of Life and Health Sciences, Link Campus University, Rome, Italy.
- Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Bydgoszcz, Poland.
- Cardiology Department, Centre of Postgraduate Medical Education, Grochowski Hospital, Warsaw, Grenadierow, Poland.
ORCID-Profile: Paul A Gurbel, Young-Hoon Jeong, Eliano Navarese, Jacek Kubica, Bogumil Ramotowski, Udaya S Tantry
Zitieren
APA
Gurbel, P. A., Jeong, Y. H., Navarese, E., Kubica, J., Ramotowski, B., & Tantry, U. S. (2026). State of the Art: Personalized Antiplatelet Therapy by Genotype and Platelet Function Testing. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70794
Vancouver
Gurbel PA, Jeong YH, Navarese E, Kubica J, Ramotowski B, Tantry US. State of the Art: Personalized Antiplatelet Therapy by Genotype and Platelet Function Testing. Catheterization and Cardiovascular Interventions. 2026. doi:10.1002/ccd.70794
BibTeX
@article{Gurbel2026,
author = {Gurbel, Paul A and Jeong, Young-Hoon and Navarese, Eliano and Kubica, Jacek and Ramotowski, Bogumil and Tantry, Udaya S},
title = {State of the Art: Personalized Antiplatelet Therapy by Genotype and Platelet Function Testing},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
doi = {10.1002/ccd.70794}
}
EUVIMED